Abstract:Background Primary familial brain calcification (PFBC, OMIM#213600), also known as Fahr’s disease, is a rare autosomal dominant or recessive neurodegenerative disorder characterized by bilateral and symmetrical microvascular calcifications affecting multiple brain regions, particularly the basal ganglia (globus pallidus, caudate nucleus, and putamen) and thalamus. The most common clinical manifestations include cognitive impairment, neuropsychiatric signs, and movement disorders. Loss-of-function mutations in SLC20A2 are the major genetic causes of PFBC. Objective This study aimed to investigate whether Slc20a2 knockout mice could recapitulate the dynamic processes and patterns of brain calcification and neurological symptoms in patients with PFBC. We comprehensively evaluated brain calcifications and PFBC-related behavioral abnormalities in Slc20a2 -deficient mice. Methods Brain calcifications were analyzed using classic calcium-phosphate staining methods. The Morris water maze, Y-maze, and fear conditioning paradigms were used to evaluate long-term spatial learning memory, working memory, and episodic memory, respectively. Sensorimotor gating was mainly assessed using the prepulse inhibition of the startle reflex program. Spontaneous locomotor activity and motor coordination abilities were evaluated using the spontaneous activity chamber, cylinder test, accelerating rotor-rod, and narrowing balance beam tests. Results Slc20a2 homozygous knockout ( Slc20a2 -HO) mice showed congenital and global developmental delay, lean body mass, skeletal malformation, and a high proportion of unilateral or bilateral eye defects. Brain calcifications were detected in the hypothalamus, ventral thalamus, and midbrain early at postnatal day 80 in Slc20a2 -HO mice, but were seldom found in Slc20a2 heterozygous knockout ( Slc20a2 -HE) mice, even at extremely old age. Slc20a2 -HO mice exhibited spatial learning memory impairments and sensorimotor gating deficits while exhibiting normal working and episodic memories. The general locomotor activity, motor balance, and coordination abilities were not statistically different between Slc20a2 -HO and wild-type mice after adjusting for body weight, which was a major confounding factor in our motor function evaluations. Conclusion The human PFBC-related phenotypes were highly similar to those in Slc20a2 -HO mice. Therefore, Slc20a2 -HO mice might be suitable for the future evaluation of neuropharmacological intervention strategies targeting cognitive and neuropsychiatric impairments.

Antisense oligonucleotides enhance SLC20A2 expression and suppress brain calcification in a humanized mouse model

Underestimated Disease Prevalence and Severe Phenotypes in Patients with Biallelic Variants: A Cohort Study of Primary Familial Brain Calcification from China

Slc20a2-Deficient Mice Exhibit Multisystem Abnormalities and Impaired Spatial Learning Memory and Sensorimotor Gating but Normal Motor Coordination Abilities

Identification of SLC20A2 deletions in patients with primary familial brain calcification

Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide

Rescue of Mis-Splicing of a Common SLC26A4 Mutant Associated with Sensorineural Hearing Loss by Antisense Oligonucleotides.

Loss of function of CMPK2 causes mitochondria deficiency and brain calcification

Effect of Allele-Specific Clcn7G213R siRNA Delivered Via a Novel Nanocarrier on Bone Phenotypes in ADO2 Mice on 129S Background

Slc20a1 and Slc20a2 regulate neuronal plasticity and cognition independently of their phosphate transport ability

Adeno-Associated Virus-Mediated RNAi against Mutant Alleles Attenuates Abnormal Calvarial Phenotypes in an Apert Syndrome Mouse Model

A splice site mutation causing exon 6 skipping in SLC20A2 gene in a primary familial brain calcification family

A framework for individualized splice-switching oligonucleotide therapy

Calcium-Enhanced Medium-Based Delivery of Splice Modulating Antisense Oligonucleotides in 2D and 3D hiPSC-Derived Neuronal Models

A Homozygous Variant in NAA60 Is Associated with Primary Familial Brain Calcification

Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression

Expanding the genetic spectrum of primary familial brain calcification due to SLC2OA2 mutations: a case series

Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis

Developing antisense oligonucleotides for a TECPR2 mutation-induced, ultra-rare neurological disorder using patient-derived cellular models

Scn8a Antisense Oligonucleotide Is Protective in Mouse Models of SCN8A Encephalopathy and Dravet Syndrome

Prenatal delivery of a therapeutic antisense oligonucleotide achieves broad biodistribution in the brain and ameliorates Angelman syndrome phenotype in mice

Antisense oligonucleotides targeting the SMN2 promoter region enhance SMN2 expression in spinal muscular atrophy cell lines and mouse model